Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), please find enclosed the Notice convening the 32nd AGM and the Annual Report of the Company including Business Responsibility and Sustainability Report, for the financial year 2024-2025.

pdf

Medicamen Biotech Ltd.

13 Aug 2025, 01:52PM

344.05

-0.68%

Company Update

Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Announcement under Regulation 30 (LODR) - Newspaper Publication

pdf

Medicamen Biotech Ltd.

12 Aug 2025, 06:36PM

344.05

-0.68%

Company Update

Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Announcement under Regulation 30 (LODR) - Change in management

pdf

Medicamen Biotech Ltd.

12 Aug 2025, 06:34PM

344.05

-0.68%

Corp. Note

Medicamen Biotech Ltd-$ - 531146 - Business Responsibility and Sustainability Reporting (BRSR)

BSE India

Business Responsibility and Sustainability Report - 2024-25

pdf

Medicamen Biotech Ltd.

12 Aug 2025, 04:35PM

344.05

-0.68%

Result

Medicamen Biotech Ltd-$ - 531146 - Outcome Of The Board Meeting Held On August 12, 2025

BSE India

Outcome of the Board meeting held on August 12, 2025

pdf

	Jun 2025	Mar 2025	Jun 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	43.52	34.84	43.63	24.9%	-0.3%
Operating Profit Qtr	4.62	-1.61	3.45	387.0%	33.9%
Net Profit Qtr	2.15	2.42	1.35	-11.2%	59.3%
Earning Per Share Adjusted latest Qtr	1.59	1.78	1.00	-10.7%	59.0%

* Consolidated data

Detailed Results

Medicamen Biotech Ltd.

07 Aug 2025

344.05

-0.68%

Board Meeting

Medicamen Biotech Ltd-$ - 531146 - Board Meeting Intimation for For Consideration And Approval Of Unaudited …

BSE India

Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve unaudited (Standalone and Consolidated) financial results for the quarter ended on June 30, 2025.

pdf